Effect of Rosuvastatin in Expression of Tim-3

The effects of Rosuvastatin in Expression of Tim-3 on NK cells and NKT cells in Patients with Chronic Hepatitis B by Flow cytometry

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190602043789N1

Enrollment

Registered

2019-10-13

Start date

2019-10-23

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis B. Chronic viral hepatitis B without delta-agent

Interventions

Intervention 1: Intervention group:15 Patients with hepatitis B received Rosuvastatin 20 mg/day from Abidi pharmaceutical company with food for a period of three months. Intervention 2: Control gro

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients with Chronic Hepatitis B Age range 20-50 years

Exclusion criteria

Exclusion criteria: Patient's unwillingness to continue participating in the study Acute kidney failure and dialysis Immune system disorders Malignancies Use of Immunosuppressive drugs Surgery over the past 3 months Statin Allergy Alcohol and drug addiction... Pregnancy Inability to visit the clinic Cirrhosis

Design outcomes

Primary

Measure	Time frame
The percentage of NK cells containing Tim3 Protein. Timepoint: Three Months after taking Rosuvastatin Tablets. Method of measurement: By kit in blood samples.;The percentage of NKT cells containing Tim3 Protein. Timepoint: Three Months after taking Rosuvastatin Tablets. Method of measurement: By kit in blood samples.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShohreh Taziki

Gorgan University of Medical Sciences

dr_sh_taziki@yahoo.com+98 17 3245 1434

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026